{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorder&page=53",
    "query": {
      "condition": "Disorder",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 145208,
    "total_pages": 14521,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorder&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorder&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:26:58.459Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05838638",
      "title": "Serious Gaming for Chemotherapy-induced Nausea and Vomiting",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neoplasms",
        "Chemotherapy-induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "eSSET-CINV",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 610,
      "start_date": "2023-06-09",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838638"
    },
    {
      "nct_id": "NCT00177138",
      "title": "Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00177138"
    },
    {
      "nct_id": "NCT00004638",
      "title": "Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sinusitis"
      ],
      "interventions": [
        {
          "name": "pathogenesis study",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004638"
    },
    {
      "nct_id": "NCT00104858",
      "title": "Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Small Lymphocytic Lymphoma",
        "T-Cell Large Granular Lymphocyte Leukemia"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2004-12",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Seattle, Washington",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104858"
    },
    {
      "nct_id": "NCT03822858",
      "title": "Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Intrathecal MSC-NP injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tisch Multiple Sclerosis Research Center of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822858"
    },
    {
      "nct_id": "NCT04690348",
      "title": "Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Craniotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cesium-131 brachytherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2020-12-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04690348"
    },
    {
      "nct_id": "NCT04500548",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lynch Syndrome",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Xeroderma Pigmentosum"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Months to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-05-11",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04500548"
    },
    {
      "nct_id": "NCT06483555",
      "title": "Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Metastatic Pancreatic Cancer",
        "Basal Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "NALIRIFOX",
          "type": "DRUG"
        },
        {
          "name": "Folfirinox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2025-02-06",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06483555"
    },
    {
      "nct_id": "NCT05419219",
      "title": "TaiChi-DTx for Treating Long Covid Symptoms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatigue",
        "Dyspnea",
        "Cognitive Impairment",
        "Muscle Pain"
      ],
      "interventions": [
        {
          "name": "the multi-domain Tai Chi Digital therapy Software Application",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Tim Shi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2022-06-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "Ellicott City, Maryland",
      "locations": [
        {
          "city": "Ellicott City",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05419219"
    },
    {
      "nct_id": "NCT06925919",
      "title": "Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rift Valley Fever"
      ],
      "interventions": [
        {
          "name": "IDB-011 dose level 1",
          "type": "DRUG"
        },
        {
          "name": "IDB-011 dose level 2",
          "type": "DRUG"
        },
        {
          "name": "IDB-011 dose level 3",
          "type": "DRUG"
        },
        {
          "name": "IDB-011 dose level 4",
          "type": "DRUG"
        },
        {
          "name": "IDB-011 dose level 5",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "IDBiologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-04-02",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-31T05:26:58.459Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06925919"
    }
  ]
}